Abstract
Given the problematic nature of tardive dyskinesia in persons taking conventional antipsychotics, evaluation of newer atypical antipsychotic agents should include a systematic assessment of tardive dyskinesia liability. Results of a prospective double-blind, randomized study of schizophrenic patients who participated in 3 preclinical olanzapine studies and were treated with 5 to 20 mg/day of olanzapine (N = 1192) or haloperidol (N = 522) recently indicated a significantly lower risk of development of tardive dyskinesia with olanzapine treatment than haloperidol treatment. This article discusses the known effects of atypical antipsychotic medications on tardive dyskinesia movements (both withdrawal and persistent) and the incidence rate of tardive dyskinesia among schizophrenic patients undergoing long-term treatment with olanzapine or haloperidol.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antipsychotic Agents / adverse effects*
-
Antipsychotic Agents / therapeutic use
-
Benzodiazepines
-
Clozapine / therapeutic use
-
Double-Blind Method
-
Drug Administration Schedule
-
Dyskinesia, Drug-Induced / epidemiology*
-
Dyskinesia, Drug-Induced / etiology
-
Dyskinesia, Drug-Induced / prevention & control
-
Haloperidol / adverse effects
-
Haloperidol / therapeutic use
-
Humans
-
Incidence
-
Molindone / adverse effects
-
Molindone / therapeutic use
-
Olanzapine
-
Pirenzepine / adverse effects
-
Pirenzepine / analogs & derivatives
-
Pirenzepine / therapeutic use
-
Prospective Studies
-
Risk Factors
-
Risperidone / adverse effects
-
Risperidone / therapeutic use
-
Schizophrenia / drug therapy
-
Substance Withdrawal Syndrome / etiology
-
Substance Withdrawal Syndrome / prevention & control
-
Survival Analysis
Substances
-
Antipsychotic Agents
-
Benzodiazepines
-
Pirenzepine
-
Clozapine
-
Haloperidol
-
Risperidone
-
Olanzapine
-
Molindone